Pembrolizumab active in the first-line setting for patients with advanced ccRCC with no unexpected toxicities.
This trial met its primary endpoint with an ORR of 40% and showed a manageable and well-tolerated safety profile for erdafitinib in FGFR-altered UC.
Enfortumab vedotin, an investigational antibody-drug conjugate, appears well tolerated in this phase I study with an ORR of 41% in previously treated patients with mUC.
Neoadjuvant therapy with atezolizumab yielded a pCR of 29% in cisplatin-ineligible patients with operable bladder cancer.
Neoadjuvant pembrolizumab associated with a pathologic CR rate of 39.5% and no surgical delay in MIBC patients scheduled for radical cystectomy.
All assessed patient-reported outcomes favored first-line therapy with atezolizumab + bevacizumab over sunitinib in mRCC.
Lenvatinib plus pembrolizumab associated with an ORR of 63% at 24 weeks and tumor size reduction in 29/30 patients.
Combination of a PARP inhibitor plus ADT increases radiologic PFS in patients with docetaxel-treated mCRPC.
In this phase II study, pembrolizumab showed antitumor activity in a subset of previously treated patients with metastatic CRPC regardless of PD-L1 expression status.
Final analysis showed survival with sunitinib alone not inferior to nephrectomy followed by sunitinib.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.